Diagnostics & Genomics
A

Allelica

Allelica, based in San Francisco, builds polygenic risk scores and sells them several ways. Laboratories and health systems license its software: modules to discover, validate and run ancestry specific scores, delivered from the cloud or on premises through the Allelica Precision Server, which also reports pharmacogenomics and carrier screening for CLIA laboratories. Clinicians can also order Allelica's own laboratory developed tests from its CLIA certified laboratory, including a coronary artery disease score, AbsoluteDx, which combines monogenic and polygenic risk, and Breast Risk Reveal, which adds the BOADICEA breast cancer model licensed from Cambridge Enterprise. For employers it runs cardioriskSCORE, a heart disease prevention program in which employees take an at home DNA test whose result is combined with traditional risk factors.

Its coronary artery disease work, published in Nature Communications in 2023 by Allelica scientists, built ancestry specific scores on 29,389 people across ancestry groups, reported an average odds ratio per standard deviation of 1.57, and improved classification of people at intermediate ten year risk in a separate cohort of 9,691. Allelica states that the 2026 ACC/AHA dyslipidemia guideline recognizes polygenic risk as a risk enhancing factor and cites its multi ancestry study.

Allelica names Mayo Clinic, Baylor College of Medicine, the University of Alabama at Birmingham, Mass General Brigham and the VA, which is running a clinical study with Allelica of polygenic risk and pharmacogenomic testing for cardiovascular prevention, among institutions working with it, and has partnered with Illumina and Thermo Fisher Scientific to bring its software to their platforms. It holds ISO 13485 and ISO 9001 quality certifications. Its published privacy policy covers the website only and dates from 2020.

AI Health Index verifiedNovember 8, 2026
Compare Allelica with other vendors
Founded
—
Headquarters
San Francisco, California, United States
Categories
diagnostics-and-genomics
Indexed Products
Allelica PRS software (Discover, Validate, Predict), Allelica Precision Server, CAD polygenic risk score test, AbsoluteDx, Breast Risk Reveal, cardioriskSCORE
Buyer Segments
Clinical laboratories, Health systems and academic medical centers, Cardiology and preventive cardiology programs, Clinicians ordering risk tests
Assessment

Capability Axes

An AI Health Index grade measures what a buyer can verify from public sources on the date shown. It is not a rating of how good the product is. A vendor can build an excellent system and grade low on an axis because it publishes nothing an outsider can check. How grades read

AI Capability
BB on AI CentralityThe model is the engine of a core module. The platform carries other value, but this capability does not exist without it.
Vendor Published

The model is the engine of the core product, and the platform carries some other value. What Allelica sells is polygenic risk scores, statistical models fitted to large genotyped cohorts with ancestry specific weights, either as software a laboratory runs or as tests from Allelica's own laboratory, and none of that exists without the models. AbsoluteDx and Breast Risk Reveal combine the scores with monogenic findings and, for breast cancer, the licensed BOADICEA model.

The Allelica Precision Server also reports pharmacogenomics and carrier screening for laboratories, which is bioinformatics reporting rather than model output, so the platform is not purely the model.

CC on Autonomy and Oversight ModelAutonomy is claimed and oversight is asserted without a mechanism. Human in the loop appears as a phrase rather than a described control.
Vendor Published

Scores reach a laboratory or an ordering clinician, and the controls around them are not described. Laboratories run Allelica's software inside their own validated tests and sign out results, and clinicians order Allelica's tests and decide what a risk estimate means for treatment, which is review before action.

What is not published is the mechanism: which ancestry or quality conditions stop a score from being reported, how scores outside validated groups are labeled, and how a recalibrated model affects scores already issued.

BB on Model and Technology TransparencyThe approach or the suppliers are named without the version and update discipline behind them. Naming a supplier is the entry to this band both here and on Model Supply Chain Disclosure, which ask different questions of the same disclosure: who receives the data, and what produces the output.
Vendor Published

The approach and a supplier are named without version and update discipline. Allelica describes ancestry specific polygenic risk scores developed and validated in named cohorts, software modules to discover, validate and run them, and the BOADICEA breast cancer model licensed from Cambridge Enterprise inside Breast Risk Reveal. Its scores run on Illumina and Thermo Fisher genotyping platforms through those partnerships.

No version history for the scores, recalibration schedule or notice to laboratories when a model changes is published.

BB on Model Supply Chain DisclosureSubstantial partial disclosure, or a chain that is structurally short: an in house build, a cleared model that cannot be quietly swapped, or a deployment where the transfer does not occur at all. Naming the model provider exits the band below into this one; the axis rises from here on the completeness of the party list and on the terms that govern data once it arrives.
Vendor Published

The chain is short and the outside model is named. Allelica builds its polygenic scores in house, licenses the BOADICEA breast cancer model from Cambridge Enterprise for Breast Risk Reveal, and offers an on premises server in which no transfer to Allelica occurs at all. Illumina and Thermo Fisher are named as platform partners.

For the cloud service, no hosting provider, subprocessor list or terms governing customer genotypes are published.

BB on Clinical and Operational EvidenceNamed deployments with dated outcome figures and enough method to test them, or published research short of independent validation.
Peer Reviewed Publication

Peer reviewed development and validation by the company's own scientists. In Nature Communications (2023), Allelica authors built ancestry specific coronary artery disease scores on 29,389 people from diverse cohorts and ancestry groups, reported an average odds ratio per standard deviation of 1.57 with 12 to 24 percent of people placed at high genetic risk, and, in a separate cohort of 9,691 people, found a net reclassification improvement of 13.14 percent (95 percent CI 9.23 to 17.06) for coronary artery disease and 10.70 percent for atherosclerotic cardiovascular disease among those at intermediate ten year risk. Allelica also lists a cost effectiveness study in the Journal of the American Heart Association and work in Circulation on polygenic risk and LDL cholesterol.

Allelica states that the 2026 ACC/AHA dyslipidemia guideline cites its multi ancestry study; that is a citation of the research rather than an independent evaluation of the product. No prospective study of outcomes in patients tested with Allelica's scores is published.

DD on AI Safety and PHI StewardshipNothing published on how protected information moves through the system.
Vendor Published

Nothing published describes how patient genetic data moves through the system. Allelica's one privacy document is a 2020 website policy that does not address genotype data, retention, research use or whether customer data trains or recalibrates the scores. The on premises Precision Server can keep data inside the laboratory, but no terms are published for the cloud service.

Safety engineering for the scores, meaning how a faulty score would be detected and handled, is not published.

Regulatory and Compliance
DD on HIPAA and BAA PostureNo statement of status and no privacy document that reaches the product. Both halves are absent at this grade: a service level privacy document on its own lifts a vendor to the band above even where no status is stated. A website privacy notice, including one that says it does not cover customer data, does not reach the product, so a vendor whose only document is that notice and who states no status grades here.
Vendor Published

No status is stated and no privacy document reaches the product. The privacy policy Allelica publishes, last updated 2 January 2020, covers its website and general service, does not mention HIPAA, genetic data or clinical testing, and predates the clinical tests it now sells from its own laboratory. No business associate position is stated for the software laboratories run on patient genotypes, and no notice of privacy practices is published for patients tested in Allelica's laboratory.

DD on Security Certifications and Trust CenterControls are asserted with nothing independent behind them, or nothing is published. Read the note before concluding anything: this is the grade most often corrected on a second pass, because assurance material frequently sits on a parent domain or inside an old announcement rather than on the product pages.
Vendor Published

Nothing independent covers information security. Allelica holds ISO 13485 and ISO 9001, which certify quality management for medical device and general processes, and a CLIA certificate for its laboratory; none is an audit of how it runs security. No SOC 2 report, HITRUST certification, ISO/IEC 27001 certificate, penetration testing statement or trust center is published, and the website privacy policy says only that commercially acceptable means protect data.

CC on FDA and Regulatory StatusNo device claim is made and the product is scoped accordingly. Most administrative and operational products sit here and are not penalized for it, because this axis grades the appropriateness of the positioning rather than possession of a clearance.
Vendor Published

No device claim is made and the tests are positioned as laboratory developed tests. Allelica says it launched its ancestry specific polygenic risk score tests as laboratory developed tests from its CLIA certified laboratory, and that the Precision Server is designed for laboratories working under CLIA. It holds ISO 13485 certification for medical device quality management and ISO 9001, which describe how it builds products rather than a clearance.

No FDA clearance or CE marking is claimed for any score, and the regulatory position of the software when another laboratory reports its scores is not stated.

CC on AI Governance and Bias DisclosureResponsible artificial intelligence is committed to in policy language with no evaluation behind it. Most of the index sits here.
Peer Reviewed Publication

Ancestry is built into the method and the group results are not set out on Allelica's pages. Polygenic scores usually perform worse outside European ancestry, and Allelica's response is ancestry specific scoring: its Nature Communications paper (2023) develops separate scores across genetic ancestry groups in 29,389 people and reports performance as an average odds ratio per standard deviation of 1.57 across them. Allelica describes the paper as showing clinical utility across ancestry groups.

The per group figures, which show where a score is weakest, are not presented on the site or in the paper's summary, and no change control or monitoring process for the models is published.

DD on AI Liability and RecourseNothing published on what happens when the system is wrong.
Vendor Published

Nothing published says what happens when a score is wrong. Allelica publishes discrimination and reclassification figures for its coronary artery disease scores, which describe how well the scores separate risk rather than how often a person is misplaced at a decision threshold.

No error rate at reporting thresholds, warranty, remediation commitment or correction route for a tested patient is published, and no notice of privacy practices sets out a patient's rights over Allelica's laboratory results.

Integration and Deployment
DD on EHR and Interoperability DepthNo integration evidence. A connector described as available on request grades here until one exists.
Vendor Published

No integration evidence is published. Allelica's software runs inside laboratories' bioinformatics workflows and reports through them, and its tests return reports to ordering clinicians, but no record system integration, standard, marketplace listing or live site is described for either route. Named institutions working with Allelica are research and implementation partners rather than integration references.

BB on Deployment Model and Data ResidencyOptions and residency are stated with isolation or the processing path left open.
Vendor Published

Options are stated, with the cloud location left open. Allelica offers its software as a cloud service and as the on premises Allelica Precision Server, sold as hardware or as containerized software, which a laboratory runs in its own environment so genotypes need not leave it. That gives a buyer a residency choice by deployment.

For the cloud service, no hosting provider, region or tenant isolation is described, and Allelica operates in the United States and Europe without saying where each customer's data rests.

Commercial
CC on Commercial TransparencyNo price is published and the posture is discoverable: a buyer can establish how the product is sold and what drives the cost before contacting the vendor. Most of the index sits here.
Vendor Published

No price is published and how the products are sold can be established. Laboratories and health systems license the software, as a cloud service or as the on premises Allelica Precision Server, and clinicians order Allelica's tests from its laboratory. Employers can buy cardioriskSCORE, an employee heart health program. The site lists the modules and tests without a license fee, per sample rate or test price, and no insurance position for the tests is stated.

BB on Setting and Specialty CoverageCoverage is named with validation behind part of it.
Vendor Published

Coverage is named with validation behind part of it. The coronary artery disease scores are validated across ancestry groups and for reclassifying people at intermediate cardiovascular risk, which is the preventive cardiology setting the guideline discussion concerns. Breast cancer risk is offered through Breast Risk Reveal and AbsoluteDx.

Employers can buy cardioriskSCORE, an employee heart disease prevention program built on an at home DNA test, and the VA is studying polygenic risk and pharmacogenomic testing with Allelica for cardiovascular prevention. Allelica lists scores for other conditions, including Alzheimer's disease, without published validation for each on its pages.

Alternatives

Alternatives to Allelica

Other products that do the same kind of work as Allelica, and what each one does.

All Allelica alternatives, with prices →

MyOme is a genomics company in Menlo Park, California, with a CLIA certified and CAP accredited laboratory, that sells whole genome screening built around integrated risk scores.

Myriad Genetics is a genetic testing company in Salt Lake City, Utah, listed on NASDAQ as MYGN, that runs its tests in its own accredited laboratories.

Genomics trades as Genomics and is registered in England as Genomics Ltd, formerly Genomics plc. Its US arm, Genomics Inc., is wholly owned by Genomics Ltd.

Genomics company in San Mateo, California, sequencing with its proprietary Exome+ assay in a CLIA certified, CAP accredited laboratory.

Multi cancer early detection company (NASDAQ: GRAL). The Galleri test uses targeted methylation sequencing of cell free DNA from a blood draw, with machine learning classifiers that detect a cancer signal and predict its origin, across more than 50 cancer types.

Veracyte sells genomic tests that pair a laboratory expression assay with a learned classifier, used by urologists, oncologists and endocrinologists to decide how intensively to treat a cancer or whether a thyroid nodule needs surgery.

Commercial

Pricing

Vendor-published figures are labeled as such. Figures labeled “Estimated” are derived from third-party sources and have not been confirmed by the vendor.

Entry Price Pricing Basis BAA Tier Implementation Source
Not published
Software licensed to laboratories and health systems as a cloud service or an on premises server; clinical tests ordered from Allelica's laboratory. No unit of charge published. Not published. No HIPAA role or business associate agreement is stated for the hosted software or the laboratory tests. Not published. Vendor Published

Allelica lists its software modules, the Allelica Precision Server and its clinical tests without a license fee, per sample rate, test price or insurance position.

Allelica pricing in full →